CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 60 enrolled
Drug / intervention
Metformin +1 moredrug
Likely dose
Metformin 425 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04826692
NCT04826692Phase 3Completed
CompareCT.gov

"Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"

Instituto de Investigacion Sanitaria La Fe·interventional·Posted Apr 1, 2021·Updated Sep 25, 2025

In Brief

A Phase 3 clinical trial evaluating Metformin and Placebo for Huntington Disease. Completed, enrolled 60 participants across 9 sites.

Detailed Summary

Multicenter, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of metformin treatment at a dose of 1700 mg / day in adults with Huntington's disease. The study consists of a screening period (2 to 4 weeks), followed by a 52-week double-blind treatment period and a follow-up visit (one month after the end of treatment).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington Disease
CountriesSpain
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedApr 1, 2021
Enrollment StartApr 11, 2022
Primary CompletionJun 10, 2025
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.3 years ago

Interventions

Metformindrug

Metformin oral: 425 mg twice daily (initial dose) and 850 twice daily (maximum dose)

Placebodrug

425 mg twice daily (initial dose) and 850 twice daily (maximum dose)